title: [Anticoagulation and Thrombembolism During Bevacizumab Treatment--To Be Careful or Fearful?].
abstract: Inhibition of angiogenesis is a valid approach in today's medicine. Besides oncology, it is used in ophthalmology, as well. In oncology, angiogenesis inhibition has become a routine and accessible method. A combination of angiogenesis inhibition and other therapies, including anticoagulation and antiaggregation is common in many cases. Bevacizumab is the most used antiangiogenic agent and has been in use for the longest period of time. A concomitant administration of angiogenesis inhibitors and anticoagulation may be feared by oncologists. From the available literature it is obvious that concomitant administration of bevacizumab and anticoagulation is safe. Also, use of antiaggregation and bevacizumab is safe. The risk of venous and arterial thromboembolism is real during the treatment with bevacizumab. Therefore, concomitant anticoagulation is not only possible but also may be desirable.
authors: Š
authors: Š
authors: Tuček
authors: A
authors: A
authors: Jurečková
authors: J
authors: J
authors: Tomášek
authors: D
authors: D
authors: Adámková Krákorová
authors: J
authors: J
authors: Halámková
authors: L
authors: L
authors: Pochop
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000925:Anticoagulants / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000009:adverse effects*; D006801:Humans; D013923:Thromboembolism / Q000139:chemically induced* / Q000517:prevention & control
chemical_list: D020533:Angiogenesis Inhibitors; D000925:Anticoagulants; D000068258:Bevacizumab